Benzinga | Apr 20, 2021 08:02AM EDT

180 Life Sciences Corp. Announces Collection Of All Patient Data For Phase 2b Dupuytren's Disease Trial

180 Life Sciences Corp. (NASDAQ:ATNF) (180 Life Sciences or the "Company"), a clinical-stage biotechnology company focused on the development of novel drugs that fulfill unmet needs in inflammatory diseases, fibrosis and pain, today announced that all patient data for the Phase 2b Dupuytren's disease clinical trial has been collected and submitted for analysis and review.